TEE
CBIO

Tibra Equities Europe’s Crescent Biopharma CBIO Stock Holding History

Tibra Equities Europe’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,361
Closed -$316K – 107
2021
Q2 		$316K Buy
+1,361
New +$346K 0.1% 157
2018
Q2 		– Sell
-719
Closed -$1.17M – 145
2018
Q1 		$1.17M Buy
+719
New +$1.5M 0.2% 75

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tibra Equities Europe's CBIO Position: Q3 2021 in Review

Tibra Equities Europe sold out of Crescent Biopharma (CBIO) in Q3 2021, closing a stake of 1,361 shares — an estimated $316K sold.

Tibra Equities Europe first reported a position in CBIO in Q1 2018 and held it in 2 quarters. The position peaked at $1.17M in Q1 2018. 47 funds tracked by Wall St. Rank hold CBIO as of Q3 2021.

  • Tibra Equities Europe reported no remaining Crescent Biopharma position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 1,361 Crescent Biopharma shares in Q3 2021, an estimated $316K.
  • Tibra Equities Europe first reported a position in Crescent Biopharma in Q1 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Crescent Biopharma position peaked at $1.17M in Q1 2018.
  • 47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.